Welcome to our dedicated page for Thermo Fisher Scientific news (Ticker: TMO), a resource for investors and traders seeking the latest updates and insights on Thermo Fisher Scientific stock.
Thermo Fisher Scientific, Inc. (TMO) is a global leader in providing science-based solutions, offering a wide range of products and services in the life sciences, analytical instruments, specialty diagnostics, and laboratory products sectors. The company's expansive portfolio includes scientific instruments, laboratory equipment, diagnostic consumables, and life science reagents, serving customers both in the United States and internationally.
Thermo Fisher operates through four distinct segments as of end-2023:
- Analytical Technologies (17% of sales): This segment focuses on providing high-quality instruments and software solutions for various scientific applications.
- Specialty Diagnostic Products (10% of sales): This segment specializes in offering diagnostic reagents and instruments for medical and research laboratories.
- Life Science Solutions (23% of sales): This segment provides reagents, instruments, and consumables used in biological research and drug development.
- Lab Products and Services (54% of sales): This is the largest segment, encompassing laboratory supplies, equipment, and contract research organization (CRO) services.
Thermo Fisher is continually expanding its offerings and capabilities through strategic partnerships, acquisitions, and technological innovation. The company's robust financial performance underscores its leadership in the industry, driven by consistent revenue growth, strong market presence, and a commitment to advancing scientific research and healthcare.
Recent achievements include technological advancements in analytical instruments, enhanced diagnostic solutions, and expanded biopharma services, reflecting Thermo Fisher's dedication to supporting life-saving research and diagnostic processes. Thermo Fisher remains committed to delivering high-quality products and services, fostering scientific breakthroughs, and maintaining its position at the forefront of scientific innovation.
Thermo Fisher Scientific (NYSE: TMO), a leader in scientific services, will have CEO Marc N. Casper present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 8:15 a.m. (EST). The presentation will cover the company's business outlook and future financial expectations. Thermo Fisher reported annual revenues of approximately $40 billion and employs over 100,000 people globally. Investors can access the webcast via the company's website.
Thermo Fisher Scientific (NYSE: TMO) announced the release of its fourth quarter and full year 2021 financial results on February 2, 2022, before market opening. The earnings call will take place at 8:30 a.m. EST on the same day. Investors can listen in via phone or the company's website. Thermo Fisher is a leader in the science sector with annual revenues around $40 billion. The company aims to support customers in various fields, including life sciences and diagnostics, with an extensive range of innovative technologies and services.
Thermo Fisher Scientific (NYSE: TMO), a leader in serving science, announced that Marc N. Casper, its CEO, will present at the 2022 Goldman Healthcare CEOs Unscripted Conference on January 6, 2022, at 9:00 a.m. EDT. This virtual event will highlight the company's initiatives in the healthcare sector. With an annual revenue of approximately $40 billion, Thermo Fisher supports various industries, including life sciences and diagnostics, through its innovative technologies and services. For more details, visit thermofisher.com.
Thermo Fisher Scientific has finalized its acquisition of PPD, Inc. for $17.4 billion, enhancing its position in the biopharma and biotech sectors. The acquisition is expected to add $1.50 to Thermo Fisher's adjusted earnings per share in 2022 and generate approximately $125 million in total synergies within three years. With this integration, Thermo Fisher expands its service offerings across clinical development, covering scientific discovery to drug manufacturing. PPD's stock has ceased trading on Nasdaq as it becomes part of Thermo Fisher's Laboratory Products and Services Segment.
BioGX announced that its SARS-CoV-2 diagnostic portfolio can detect the Omicron variant (B.1.1.529). The surveillance program includes in-silico analyses confirming detection across all variants of interest. BioGX's COVID-19 RT-PCR tests are compatible with several real-time PCR platforms, notably the Xfree COVID-19 Direct RT-PCR, which is FDA authorized for multiple specimen types. This test offers extraction-free options, enhancing workflow efficiency. BioGX operates under ISO 13485 standards, providing over 60 multiplex real-time PCR products worldwide.
Thermo Fisher Scientific (NYSE:TMO) confirmed that its TaqPath COVID-19 tests accurately detect the Omicron variant, ensuring reliable results despite the variant's mutations. The tests, which target three gene regions, remain unaffected in accuracy due to the unaffected orf1a/b and N gene targets. New TaqPath COVID-19 2.0 tests utilize eight gene targets to detect SARS-CoV-2 effectively. This capability is crucial for tracking the Omicron variant's spread and supporting global pandemic response efforts.
Thermo Fisher Scientific (NYSE:TMO) announced its plan to redeem Senior Notes totaling approximately $2.2 billion on December 3, 2021. The redemption includes $1.1 billion of 4.133% Senior Notes due 2025 and $1.1 billion of 4.497% Senior Notes due 2030. Investors will receive the greater of the principal amount or the present value of remaining scheduled payments, plus accrued interest. The company will fund the redemption using cash on hand. This move highlights the firm's commitment to managing its debt effectively.
Thermo Fisher Scientific (NYSE: TMO) has priced a €2.8 billion offering of euro-denominated senior notes, which includes €1.7 billion in floating rate notes, €550 million in 0.000% senior notes due 2023, and €550 million in sustainability notes due 2025. The offering is expected to close around November 18, 2021. Proceeds will be used to support the acquisition of PPD, Inc. and for general corporate purposes. The sustainability notes aim to fund eligible green projects. The offering complies with SEC regulations and is targeted at professional investors.
Thermo Fisher Scientific (NYSE: TMO) declared a quarterly cash dividend of $0.26 per common share, payable on January 14, 2022, to shareholders of record by December 15, 2021. The company, a leader in serving science with around $35 billion in annual revenue, aims to enhance health, cleanliness, and safety globally. They support life sciences research, diagnostics, and laboratory productivity through their renowned brands, including Thermo Scientific and Applied Biosystems.
Thermo Fisher Scientific (NYSE: TMO) has unveiled a suite of advanced mass spectrometry instruments and software at the ASMS 2021 Conference in Philadelphia. The new offerings, including the Orbitrap Exploris MX, aim to streamline biopharmaceutical development and quality control processes. Notable enhancements include the MAM 2.0 workflow, which integrates multiple assays into one analysis, and innovative software solutions like Proteome Discoverer 3.0 and Compound Discoverer 3.3, leveraging AI for improved data analysis. Thermo Fisher reported annual revenue of approximately $35 billion.
FAQ
What is the current stock price of Thermo Fisher Scientific (TMO)?
What is the market cap of Thermo Fisher Scientific (TMO)?
What does Thermo Fisher Scientific, Inc. specialize in?
What are the main segments of Thermo Fisher Scientific?
How much of Thermo Fisher's sales come from Lab Products and Services?
Where does Thermo Fisher Scientific operate?
What recent achievements has Thermo Fisher Scientific made?
What is Thermo Fisher Scientific's stock symbol?
How does Thermo Fisher Scientific support scientific research?
What types of products does Thermo Fisher Scientific offer?
What is Thermo Fisher's commitment to the healthcare industry?
What sets Thermo Fisher Scientific apart in its industry?
